Publications by authors named "T Furuichi"

Analysis of genome-scale evolution has been difficult in large, endangered animals because opportunities to collect high-quality genetic samples are limited. There is a need for novel field-friendly, cost-effective genetic techniques. This study conducted an exome-wide analysis of a total of 42 chimpanzees (Pan troglodytes) across six African regions, providing insights into population discrimination techniques.

View Article and Find Full Text PDF

Bone morphogenetic protein 2 (BMP2) is clinically applied for treating intractable fractures and promoting spinal fusion because of its osteogenic potency. However, adverse effects following the release of supraphysiological doses of BMP2 from collagen carriers are widely reported. Nanoclay gel (NC) is attracting attention as a biomaterial, given the potential for localized efficacy of administered agents.

View Article and Find Full Text PDF

Background: Nonunion following fracture treatment remains a significant clinical challenge, adversely affecting the patient's quality of life and imposing a substantial economic burden. The emergence of bone morphogenetic protein 2 (BMP-2) for bone regeneration represents a promising avenue, albeit limited by side effects such as inflammatory reactions primarily due to suboptimal drug delivery systems. This study focuses on NOVOSIS putty (NP), a novel biomaterial designed for the sustained release of BMP-2, aiming to mitigate these limitations and enhance bone healing.

View Article and Find Full Text PDF
Article Synopsis
  • * Studies show that the loss of the Men1 protein in osteoblasts leads to structural bone changes similar to those observed in osteoporosis patients, characterized by decreased bone-forming and increased bone-resorbing activities.
  • * The research suggests that loss of Men1 triggers cellular senescence via mTORC1 activation and AMPK suppression, with potential treatment benefits from metformin, indicating a new avenue for therapeutic strategies against age-related osteoporosis.
View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to assess the safety and pharmacokinetics of a new drug, BI 1291583, which inhibits cathepsin C to potentially reduce inflammation in bronchiectasis patients.
  • Conducted as a randomized, double-blind, placebo-controlled trial, it involved healthy Japanese males and evaluated both single and multiple doses for any related adverse events and drug absorption levels.
  • Results indicated that the drug was safe and well-tolerated, with no serious side effects and an adequate benefit-risk ratio, suggesting it can be used in future clinical trials involving bronchiectasis patients without needing dose adjustments.
View Article and Find Full Text PDF